Capdevila, J.Landolfi, S.Hernando, J.Teule, A.Garcia-Carbonero, R.Custodio, A.Cubillo, A.Alonso-Gordoa, T.Carmona-Bayonas, A.Crespo, G.Blanco, M.Viudez, A.La Casta, A.Sevilla, I.Segura, A.Lopez, C.Benavent Vinuales, M.Nuciforo, P.Manzano, J. L.2025-01-072025-01-072021-09-21J. Capdevila , S. Landolfi , J. Hernando , A. Teule , R. Garcia-Carbonero , A. Custodio, et al. Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601). Annals of Oncology, 2021, (32), S914 - S9150923-7534https://hdl.handle.net/10668/27028Background.Previously reported treatment efficacy with durvalumab (D) plus tremelimumab (T) showed limited activity in patients (pts) with well differentiated neuroendocrine tumors (NETs). However, primary endpoint was achieved in grade 3 (G3) neuroendocrine neoplasms (NENs) suggesting a promising overall survival rate in a pretreated population. Here we update the results of the G3 cohort with central pathological review.Methods.DUNE was a prospective open-label trial that recruited pts with advanced NENs after progression to standard therapies in four cohorts (C1-4): typical/atypical lung carcinoids (C1), G1/2 gastrointestinal (C2), G1/2 pancreatic (C3), and G3 NENs of gastroenteropancreatic origin after progression to first-line platinum-based chemotherapy (C4). Pts received 1500 mg durvalumab (D) (up to 13 cycles) plus 75 mg tremelimumab (T)(up to 4 cycles) once every 4 weeks. Primary objective for C4 was the 9 months (m) overall survival rate (OS) expected to be over 23%.enHumansNeuroendocrine TumorsSurvival RateCarcinoid TumorGastrointestinal NeoplasmsTreatment OutcomeLungdurvalumabtremelimumabPlatinumProspective StudiesCarcinoma, NeuroendocrineTreatment Outcomeconference outputRestricted AccessTasa de supervivenciaResultado del tratamientoPulmónTumores neuroendocrinosMétodosNeoplasiasQuimioterapiaPlatino (Metal)Tumor carcinoide10.1016/j.annonc.2021.08.1891569-8041https://doi.org/10.1016/j.annonc.2021.08.189700527702125